X4 Pharmaceuticals (XFOR) said Friday that its marketing authorization application for mavorixafor to treat WHIM syndrome has been validated for review by the European Medicines Agency.
The EMA previously granted mavorixafor orphan drug designation to treat WHIM syndrome, a rare genetic disease that impairs the body's immune system and is characterized by recurrent infections, skin warts, and an increased risk of cancer.
The treatment is sold in the US under the Xolremdi brand name following approval last April by the US Food and Drug Administration to treat WHIM syndrome in patients 12 years of age and older.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.